Search

Daiichi Sankyo Antibody-Pyrrolobenzodiazepine Derivative Conjugate Cancer Therapy Patent

The USPTO granted patent US12606634B2 to Daiichi Sankyo Company, Limited on April 21, 2026, covering a novel antibody-pyrrolobenzodiazepine derivative conjugate that binds claudin-6 (CLDN6) and claudin-9 (CLDN9) proteins, with applications in cancer therapy. The patent contains 17 claims under CPC classifications A61K 47/6803, A61P 35/00, C07D 487/04, and C07K 16/30.

Daiichi Sankyo SF-1 Antagonist 3-Phenylpropylamine Derivative Patent

The USPTO granted patent US12606533B2 to Daiichi Sankyo Company, Limited for a 3-phenylpropylamine derivative compound exhibiting SF-1 antagonist activity. The patent contains 29 claims and relates to the compound as well as polyfunctional molecules containing the compound moiety, including SF-1 degraders.